Art. -Nr.: HY-N0402

Copy Link Print Information

Artemether

(Synonyms: Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.38%
CAS. Nr.: 71963-77-4
Formel: C₁₆H₂₆O₅
Molecular Weight:298.37

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Artemether Chemical Structure

CAS. Nr.: 71963-77-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria^[1].

IC₅₀ & Target

Plasmodium

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	8.54 μM Compound: 1d	Anticancer activity against human A549 cells by sulforhodamine B assay Anticancer activity against human A549 cells by sulforhodamine B assay	[PMID: 19819696]
CHO	IC₅₀	>100 μM Compound: ARM	Cytotoxicity against CHO cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27448920]
CHO	IC₅₀	>100 μM Compound: ARM	Cytotoxicity against CHO cells assessed as reduction in cell viability by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability by MTT assay	[PMID: 32987134]
Ehrlich	IC₅₀	14.3 μM Compound: 3	Cytotoxicity against mouse EAC after 3 days by MTT assay Cytotoxicity against mouse EAC after 3 days by MTT assay	[PMID: 8350087]
HCT-116	IC₅₀	8.6 μM Compound: ATM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by Cell-titer Glo luminescent assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by Cell-titer Glo luminescent assay	[PMID: 38287228]
HCT-15	IC₅₀	9.66 μM Compound: 1d	Anticancer activity against human HCT15 cells by sulforhodamine B assay Anticancer activity against human HCT15 cells by sulforhodamine B assay	[PMID: 19819696]
HepG2	IC₅₀	<1 μM Compound: Artemether	Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin	[PMID: 23927658]
HFF	IC₅₀	0.31 μM Compound: Artemether	Antiparasitic activity against Toxoplasma gondii 2F infected in HFF cells assessed as beta galactosidase activity after 5 days Antiparasitic activity against Toxoplasma gondii 2F infected in HFF cells assessed as beta galactosidase activity after 5 days	[PMID: 20373807]
PBMC	IC₅₀	>100000 nM Compound: 3	Cytotoxicity against PHA-stimulated human PBMC cells after 48 hrs by Alamar Blue assay Cytotoxicity against PHA-stimulated human PBMC cells after 48 hrs by Alamar Blue assay	[PMID: 23673218]
SK-MEL-2	IC₅₀	7.24 μM Compound: 1d	Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay	[PMID: 19819696]
SK-OV-3	IC₅₀	8.03 μM Compound: 1d	Anticancer activity against human SKOV3 cells by sulforhodamine B assay Anticancer activity against human SKOV3 cells by sulforhodamine B assay	[PMID: 19819696]
T-cell	IC₅₀	3.82 x 10^-6 M Compound: Artemether	In vitro concentration of compound required to inhibit ConA-induced T cell proliferation to 50% in BALB/c mice In vitro concentration of compound required to inhibit ConA-induced T cell proliferation to 50% in BALB/c mice	[PMID: 15999998]
XF498	IC₅₀	9.1 μM Compound: 1d	Anticancer activity against human XF498 cells by sulforhodamine B assay Anticancer activity against human XF498 cells by sulforhodamine B assay	[PMID: 19819696]

In Vitro

Artemether (0-200 μg/mL, 24-72 h) inhibits rat C6 glioma cell growth in a dose- and time-dependent manner^[2].
Artemether (0-10 μM, 72 h) inhibits RANKL-induced osteoclast (osteoclast precursor cells (BMMs)) formation and related gene expression (TRAP, NFATc1, V-ATPase-d2, CTSK, DC-STAMP, MMP-9)^[2].
Artemether (48 or 96 h) inhibits ConA- or alloantigen-induced BALB/c splenocyte proliferation (IC₅₀: 6.3 and 3.5 μM)^[4].
Artemether (0-50 μM, 16-36 h) inhibits production of the IL-2 and IFN-γ in BALB/c splenocyte^[4].
Artemether (0-50 μM, 72 h) inhibits ConA-induced splenocyte, CD4+T- and CD8+ T-cell divisions, and inhibits cell cycle progression through G1/S transition^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

RAW264.7 cells (treated with 100 ng/mL RANKL)
Concentration:

10 μM
Incubation Time:

6 h
Result:

Inhibited the activation of MAPK subfamilies, including ERK, JNK, and p38.

Cell Cycle Analysis^[4]

Cell Line:

ConA-stimulated T lymphocytes
Concentration:

1, 10 and 50 μM
Incubation Time:

72 h
Result:

Arrested 47, 56 and 91% (at 1, 10 and 50 μM) of the cells at G0/G1 phases, respectively.

In Vivo

Artemether (0-66 mg/kg, p.o.) inhibits tumor growth and angiogenesis in SD rats bearing C6 glioma cells^[2].
Artemether (10 mg/kg, i.p., 8 days) protects mice against LPS-induced osteolytic bone loss^[3].
Artemether (50 and 100 mg/kg, p.o.) inhibits T-cell-mediated immune responses (ear swelling) in DNFB-induced DTH model in BALB/c mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

LPS (5 mg/kg) treated mice^[3]
Dosage:

10 mg/kg
Administration:

i.p., 8 days
Result:

Prevented LPS induced osteolytic bone loss and the reduction in bone volume.
Increased bone volume/total volume (BV/TV), decreased osteoclast surface/bone surface (Oc.S/BS) and number of TRAP-positive cells.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 71963-77-4
Appearance Solid
Molecular Weight 298.37
Formel C₁₆H₂₆O₅
Color White to off-white
SMILES

C[C@H]1[C@@H](OC)O[C@@]2([H])[C@]34[C@@]([C@H](C)CC[C@]41[H])([H])CC[C@@](O2)(C)OO3
Synonyms

Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All OthersIn Vivo Efficacy StudyIF

Sort by:

Journal Impact Factor

Cell Mol Life Sci

The contrasting effects of two antimalarial drugs on insulin secretion. [Abstract]

2025 Nov 25;82(1):419. PMID: 41288707

Artemether purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Nov 25;82(1):419. [Abstract]

KCl-induced insulin secretion of islets using 0,100 and 200 µM Artemether.

Artemether purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Nov 25;82(1):419. [Abstract]

Long-term Artemether (20 mg/kg/d) treatment decreased glucose-induced and KCl-induced insulin secretion by islets.

Artemether purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Nov 25;82(1):419. [Abstract]

Immunohistochemical staining of insulin after artemether treatment (Con: DMSO, Art: artemether). Green means insulin expression and blue means DAPI.
J Nutr Biochem

Artemisinin and its derivatives modulate glucose homeostasis and gut microbiota remodeling in a nutritional context. [Abstract]

2024 Sep:131:109687. PMID: 38866191
Loughborough University

2025.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (335.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3515 mL

16.7577 mL

33.5154 mL

5 mM

0.6703 mL

3.3515 mL

6.7031 mL

10 mM

0.3352 mL

1.6758 mL

3.3515 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 1.25 mg/mL (4.19 mM); Clear solution

Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (4.19 mM); Clear solution

Protocol 6

Add each solvent one by one: 5% DMSO 95% Corn Oil

Solubility: 1.25 mg/mL (4.19 mM); Suspended solution; Need ultrasonic

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 6.02 mg/mL (20.18 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Xiao, S., et al., Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop, 2002. 82(2): p. 175-81. [Content Brief]

[2]. Wu, Z.P., et al., Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. Integr Cancer Ther, 2009. 8(1): p. 88-92. [Content Brief]

[3]. Wu H, et al. Artemether attenuates LPS-induced inflammatory bone loss by inhibiting osteoclastogenesis and bone resorption via suppression of MAPK signaling pathway. Cell Death Dis. 2018 May 1;9(5):498. [Content Brief]

[4]. Wang JX, et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol. 2007 Mar;150(5):652-61. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3515 mL	16.7577 mL	33.5154 mL	83.7886 mL
	5 mM	0.6703 mL	3.3515 mL	6.7031 mL	16.7577 mL
	10 mM	0.3352 mL	1.6758 mL	3.3515 mL	8.3789 mL
	15 mM	0.2234 mL	1.1172 mL	2.2344 mL	5.5859 mL
	20 mM	0.1676 mL	0.8379 mL	1.6758 mL	4.1894 mL
	25 mM	0.1341 mL	0.6703 mL	1.3406 mL	3.3515 mL
	30 mM	0.1117 mL	0.5586 mL	1.1172 mL	2.7930 mL
	40 mM	0.0838 mL	0.4189 mL	0.8379 mL	2.0947 mL
	50 mM	0.0670 mL	0.3352 mL	0.6703 mL	1.6758 mL
	60 mM	0.0559 mL	0.2793 mL	0.5586 mL	1.3965 mL
	80 mM	0.0419 mL	0.2095 mL	0.4189 mL	1.0474 mL
	100 mM	0.0335 mL	0.1676 mL	0.3352 mL	0.8379 mL

Keywords

Artemether

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Artemether

NMPA-Approved Drug Library

Terpenoids Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Pediatric Drug Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Artemether

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Artemether Related Classifications

HY-N0402 Related Classifications